Reuters logo
BRIEF-Erytech reports determination of the recommended pivotal phase 3 dose of eryaspase in its U.S. Phase 1 study
September 28, 2017 / 6:26 AM / in 19 days

BRIEF-Erytech reports determination of the recommended pivotal phase 3 dose of eryaspase in its U.S. Phase 1 study

Sept 28 (Reuters) - ERYTECH PHARMA SA:

* ERYTECH REPORTS DETERMINATION OF THE RECOMMENDED PIVOTAL PHASE 3 DOSE OF ERYASPASE IN ITS U.S. PHASE 1 STUDY IN FIRST LINE ADULT ALL

* DOSE OF 100 U/KG WAS RECOMMENDED FOR FURTHER EVALUATION OF ERYASPASE IN PIVOTAL STUDY IN FIRST LINE ADULT ALL​

* CO WILL ALSO POTENTIALLY INITIATE LAUNCH OF PIVOTAL PHASE 3 STUDY IN FIRST LINE ADULT ALL PATIENTS AT SAME DOSE LEVEL AS FOR PHASE 1‍​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below